{"data_date":"2026-11-08","library_size":29380,"matched_against":"each record's title and abstract (summary field), case-insensitive","n":211,"page":"https://alzhub.org/answers/aducanumab","query":"title or abstract mentions \"aducanumab\", \"Aduhelm\" or \"BIIB037\"","studies":[{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/fda-grants-accelerated-approval-for-aduhelm-aducanumab-as-the-first-18854f0d","doi":null,"journal":"U.S. Food and Drug Administration (announced via Biogen press release)","n_participants":null,"pmid":null,"source_url":"https://investors.biogen.com/news-releases/news-release-details/fda-grants-accelerated-approval-aduhelmtm-first-and-only","study_design":"regulatory decision","title":"FDA Grants Accelerated Approval for ADUHELM (aducanumab) as the First and Only Alzheimer's Disease Treatment to Address a Defining Pathology of the Disease","title_match":true,"year":2021},{"alzhub_score":11,"alzhub_url":"https://alzhub.org/study/biogen-to-realign-resources-for-alzheimer-s-disease-franchise-aduhelm-49a9a379","doi":null,"journal":"Biogen Inc. press release","n_participants":null,"pmid":null,"source_url":"https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise","study_design":"company announcement","title":"Biogen to Realign Resources for Alzheimer's Disease Franchise (Aduhelm discontinuation)","title_match":true,"year":2024},{"alzhub_score":82,"alzhub_url":"https://alzhub.org/study/two-randomized-phase-3-studies-of-aducanumab-in-early-alzheimer-s-35542991","doi":"10.14283/jpad.2022.30","journal":"The journal of prevention of Alzheimer's disease","n_participants":1638,"pmid":"35542991","source_url":"https://pubmed.ncbi.nlm.nih.gov/35542991/","study_design":"clinical trial","title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease","title_match":true,"year":2022},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/cost-effectiveness-of-aducanumab-and-donanemab-for-early-alzheimer-b0c356d3","doi":null,"journal":"JAMA Neurology","n_participants":null,"pmid":null,"source_url":"https://jamanetwork.com/journals/jamaneurology/fullarticle/2790531","study_design":"modelling","title":"Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US","title_match":true,"year":2022},{"alzhub_score":74,"alzhub_url":"https://alzhub.org/study/clinically-important-benefits-and-harms-of-monoclonal-antibodies-38253509","doi":"10.1370/afm.3050","journal":"Annals of Family Medicine","n_participants":23202,"pmid":"38253509","source_url":"https://pubmed.ncbi.nlm.nih.gov/38253509/","study_design":"meta-analysis","title":"Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis","title_match":false,"year":2024},{"alzhub_score":49,"alzhub_url":"https://alzhub.org/study/cost-effectiveness-of-traditional-and-novel-neurotherapeutic-agents-41837605","doi":"10.1177/13872877261430376","journal":"Journal of Alzheimer's Disease","n_participants":null,"pmid":"41837605","source_url":"https://pubmed.ncbi.nlm.nih.gov/41837605/","study_design":"systematic-review","title":"Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review","title_match":false,"year":2026},{"alzhub_score":52,"alzhub_url":"https://alzhub.org/study/the-role-of-amyloid-pet-in-imaging-neurodegenerative-disorders-a-35649652","doi":"10.2967/jnumed.121.263195","journal":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","n_participants":null,"pmid":"35649652","source_url":"https://pubmed.ncbi.nlm.nih.gov/35649652/","study_design":null,"title":"The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review","title_match":false,"year":2022},{"alzhub_score":57,"alzhub_url":"https://alzhub.org/study/alzheimer-disease-neuropathology-in-a-patient-previously-treated-with-35581440","doi":"10.1007/s00401-022-02433-4","journal":"Acta neuropathologica","n_participants":null,"pmid":"35581440","source_url":"https://pubmed.ncbi.nlm.nih.gov/35581440/","study_design":"case report","title":"Alzheimer disease neuropathology in a patient previously treated with aducanumab","title_match":true,"year":2022},{"alzhub_score":62,"alzhub_url":"https://alzhub.org/study/impact-of-reference-and-target-region-selection-on-amyloid-pet-suv-29777003","doi":"10.2967/jnumed.118.209130","journal":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","n_participants":null,"pmid":"29777003","source_url":"https://pubmed.ncbi.nlm.nih.gov/29777003/","study_design":null,"title":"Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab","title_match":true,"year":2019},{"alzhub_score":44,"alzhub_url":"https://alzhub.org/study/amyloid-pet-a-questionable-single-primary-surrogate-efficacy-measure-36278356","doi":"10.3233/jad-220841","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"36278356","source_url":"https://pubmed.ncbi.nlm.nih.gov/36278356/","study_design":null,"title":"Amyloid PET: A Questionable Single Primary Surrogate Efficacy Measure on Alzheimer Immunotherapy Trials","title_match":false,"year":2022},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/fdg-pet-and-mri-for-monitoring-immunotherapy-in-alzheimer-disease-37314733","doi":"10.1097/rlu.0000000000004710","journal":"Clinical nuclear medicine","n_participants":null,"pmid":"37314733","source_url":"https://pubmed.ncbi.nlm.nih.gov/37314733/","study_design":null,"title":"FDG PET (and MRI) for Monitoring Immunotherapy in Alzheimer Disease","title_match":false,"year":2023},{"alzhub_score":42,"alzhub_url":"https://alzhub.org/study/advanced-brain-imaging-for-the-diagnosis-of-alzheimer-disease-37639461","doi":"10.1097/wco.0000000000001198","journal":"Current opinion in neurology","n_participants":null,"pmid":"37639461","source_url":"https://pubmed.ncbi.nlm.nih.gov/37639461/","study_design":null,"title":"Advanced brain imaging for the diagnosis of Alzheimer disease","title_match":false,"year":2023},{"alzhub_score":72,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-and-amyloid-targeting-35099507","doi":"10.1001/jamaneurol.2021.5205","journal":"JAMA neurology","n_participants":null,"pmid":"35099507","source_url":"https://pubmed.ncbi.nlm.nih.gov/35099507/","study_design":"systematic review","title":"Amyloid-Related Imaging Abnormalities and \u03b2-Amyloid-Targeting Antibodies: A Systematic Review","title_match":false,"year":2022},{"alzhub_score":83,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-in-2-phase-3-studies-evaluating-34807243","doi":"10.1001/jamaneurol.2021.4161","journal":"JAMA neurology","n_participants":1087,"pmid":"34807243","source_url":"https://pubmed.ncbi.nlm.nih.gov/34807243/","study_design":"clinical trial","title":"Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease","title_match":true,"year":2022},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/targeting-amyloid-pathology-in-early-alzheimer-s-the-promise-of-39998021","doi":"10.3390/pharmacy13010023","journal":"Pharmacy (Basel, Switzerland)","n_participants":null,"pmid":"39998021","source_url":"https://pubmed.ncbi.nlm.nih.gov/39998021/","study_design":"clinical trial","title":"Targeting Amyloid Pathology in Early Alzheimer's: The Promise of Donanemab-Azbt","title_match":false,"year":2025},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-with-anti-amyloid-antibodies-35401412","doi":"10.3389/fneur.2022.862369","journal":"Frontiers in neurology","n_participants":null,"pmid":"35401412","source_url":"https://pubmed.ncbi.nlm.nih.gov/35401412/","study_design":null,"title":"Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease","title_match":false,"year":2022},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/drug-treatments-in-alzheimer-s-disease-27251914","doi":"10.7861/clinmedicine.16-3-247","journal":"Clinical medicine (London, England)","n_participants":null,"pmid":"27251914","source_url":"https://pubmed.ncbi.nlm.nih.gov/27251914/","study_design":null,"title":"Drug treatments in Alzheimer's disease","title_match":false,"year":2016},{"alzhub_score":54,"alzhub_url":"https://alzhub.org/study/cost-effectiveness-of-aducanumab-and-donanemab-for-early-alzheimer-35344024","doi":"10.1001/jamaneurol.2022.0315","journal":"JAMA neurology","n_participants":null,"pmid":"35344024","source_url":"https://pubmed.ncbi.nlm.nih.gov/35344024/","study_design":"clinical trial","title":"Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US","title_match":true,"year":2022},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-in-alzheimer-disease-treated-37651273","doi":"10.1148/rg.230009","journal":"Radiographics : a review publication of the Radiological Society of North America, Inc","n_participants":null,"pmid":"37651273","source_url":"https://pubmed.ncbi.nlm.nih.gov/37651273/","study_design":null,"title":"Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti-Amyloid-\u03b2 Therapy","title_match":false,"year":2023},{"alzhub_score":60,"alzhub_url":"https://alzhub.org/study/association-of-microglial-activation-with-spontaneous-aria-e-and-csf-35940900","doi":"10.1212/wnl.0000000000200892","journal":"Neurology","n_participants":null,"pmid":"35940900","source_url":"https://pubmed.ncbi.nlm.nih.gov/35940900/","study_design":"longitudinal study","title":"Association of Microglial Activation With Spontaneous ARIA-E and CSF Levels of Anti-A\u03b2 Autoantibodies","title_match":false,"year":2022},{"alzhub_score":54,"alzhub_url":"https://alzhub.org/study/quantification-of-amyloid-pet-for-future-clinical-use-a-state-of-the-35389071","doi":"10.1007/s00259-022-05784-y","journal":"European journal of nuclear medicine and molecular imaging","n_participants":null,"pmid":"35389071","source_url":"https://pubmed.ncbi.nlm.nih.gov/35389071/","study_design":null,"title":"Quantification of amyloid PET for future clinical use: a state-of-the-art review","title_match":false,"year":2022},{"alzhub_score":57,"alzhub_url":"https://alzhub.org/study/the-amyloid-hypothesis-in-alzheimer-disease-new-insights-from-new-35177833","doi":"10.1038/s41573-022-00391-w","journal":"Nature reviews. Drug discovery","n_participants":null,"pmid":"35177833","source_url":"https://pubmed.ncbi.nlm.nih.gov/35177833/","study_design":null,"title":"The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics","title_match":false,"year":2022},{"alzhub_score":60,"alzhub_url":"https://alzhub.org/study/eligibility-for-anti-amyloid-treatment-in-a-population-based-study-of-37586881","doi":"10.1212/wnl.0000000000207770","journal":"Neurology","n_participants":null,"pmid":"37586881","source_url":"https://pubmed.ncbi.nlm.nih.gov/37586881/","study_design":"cross-sectional","title":"Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging","title_match":false,"year":2023},{"alzhub_score":46,"alzhub_url":"https://alzhub.org/study/can-we-learn-lessons-from-the-fda-s-approval-of-aducanumab-34535787","doi":"10.1038/s41582-021-00557-x","journal":"Nature reviews. Neurology","n_participants":null,"pmid":"34535787","source_url":"https://pubmed.ncbi.nlm.nih.gov/34535787/","study_design":null,"title":"Can we learn lessons from the FDA's approval of aducanumab?","title_match":true,"year":2021},{"alzhub_score":46,"alzhub_url":"https://alzhub.org/study/a-comparative-study-of-the-effects-of-aducanumab-and-scanning-33836798","doi":"10.1186/s13195-021-00809-4","journal":"Alzheimer's research & therapy","n_participants":null,"pmid":"33836798","source_url":"https://pubmed.ncbi.nlm.nih.gov/33836798/","study_design":null,"title":"A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease","title_match":true,"year":2021},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/vessels-sing-their-arias-the-role-of-vascular-amyloid-in-the-age-of-34905943","doi":"10.1161/strokeaha.121.036873","journal":"Stroke","n_participants":null,"pmid":"34905943","source_url":"https://pubmed.ncbi.nlm.nih.gov/34905943/","study_design":null,"title":"Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab","title_match":true,"year":2022},{"alzhub_score":42,"alzhub_url":"https://alzhub.org/study/an-intranasally-delivered-peptide-drug-ameliorates-cognitive-decline-28356312","doi":"10.15252/emmm.201606666","journal":"EMBO molecular medicine","n_participants":null,"pmid":"28356312","source_url":"https://pubmed.ncbi.nlm.nih.gov/28356312/","study_design":null,"title":"An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice","title_match":false,"year":2017},{"alzhub_score":49,"alzhub_url":"https://alzhub.org/study/cost-effectiveness-and-value-based-pricing-of-aducanumab-for-patients-35022306","doi":"10.1212/wnl.0000000000013314","journal":"Neurology","n_participants":null,"pmid":"35022306","source_url":"https://pubmed.ncbi.nlm.nih.gov/35022306/","study_design":null,"title":"Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease","title_match":true,"year":2022},{"alzhub_score":59,"alzhub_url":"https://alzhub.org/study/genome-wide-association-studies-of-aria-from-the-aducanumab-phase-3-38165296","doi":"10.1212/wnl.0000000000207919","journal":"Neurology","n_participants":1691,"pmid":"38165296","source_url":"https://pubmed.ncbi.nlm.nih.gov/38165296/","study_design":"clinical trial","title":"Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies","title_match":true,"year":2024},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/aducanumab-use-in-symptomatic-alzheimer-disease-evidence-in-focus-35197360","doi":"10.1212/wnl.0000000000200176","journal":"Neurology","n_participants":null,"pmid":"35197360","source_url":"https://pubmed.ncbi.nlm.nih.gov/35197360/","study_design":"clinical trial","title":"Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus [RETIRED]: A Report of the AAN Guidelines Subcommittee","title_match":true,"year":2022},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/omicsynth-an-open-multi-omic-community-resource-for-identifying-38181731","doi":"10.1016/j.ajhg.2023.12.006","journal":"American journal of human genetics","n_participants":null,"pmid":"38181731","source_url":"https://pubmed.ncbi.nlm.nih.gov/38181731/","study_design":null,"title":"omicSynth: An open multi-omic community resource for identifying druggable targets across neurodegenerative diseases","title_match":false,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/therapeutic-anti-amyloid-antibodies-cause-neuronal-disturbances-36515320","doi":"10.1002/alz.12833","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"36515320","source_url":"https://pubmed.ncbi.nlm.nih.gov/36515320/","study_design":null,"title":"Therapeutic anti-amyloid \u03b2 antibodies cause neuronal disturbances","title_match":false,"year":2023},{"alzhub_score":67,"alzhub_url":"https://alzhub.org/study/neuropathological-changes-and-amyloid-related-imaging-abnormalities-41109234","doi":"10.1016/s1474-4422(25)00313-8","journal":"The Lancet. Neurology","n_participants":null,"pmid":"41109234","source_url":"https://pubmed.ncbi.nlm.nih.gov/41109234/","study_design":"case-control study","title":"Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control study","title_match":true,"year":2025},{"alzhub_score":56,"alzhub_url":"https://alzhub.org/study/refractory-status-epilepticus-in-a-patient-with-aducanumab-induced-39121445","doi":"10.1212/wnl.0000000000209582","journal":"Neurology","n_participants":null,"pmid":"39121445","source_url":"https://pubmed.ncbi.nlm.nih.gov/39121445/","study_design":"longitudinal study","title":"Refractory Status Epilepticus in a Patient With Aducanumab-Induced Amyloid-Related Imaging Abnormalities","title_match":true,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/new-and-emerging-drug-therapies-for-alzheimer-disease-38962384","doi":"10.18773/austprescr.2024.021","journal":"Australian prescriber","n_participants":null,"pmid":"38962384","source_url":"https://pubmed.ncbi.nlm.nih.gov/38962384/","study_design":null,"title":"New and emerging drug therapies for Alzheimer disease","title_match":false,"year":2024},{"alzhub_score":34,"alzhub_url":"https://alzhub.org/study/what-have-we-learned-from-past-failures-of-investigational-drugs-for-34890262","doi":"10.1080/13543784.2021.2017881","journal":"Expert opinion on investigational drugs","n_participants":null,"pmid":"34890262","source_url":"https://pubmed.ncbi.nlm.nih.gov/34890262/","study_design":null,"title":"What have we learned from past failures of investigational drugs for Alzheimer's disease?","title_match":false,"year":2021},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/making-the-case-for-the-accelerated-withdrawal-of-aducanumab-35491796","doi":"10.3233/jad-220264","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"35491796","source_url":"https://pubmed.ncbi.nlm.nih.gov/35491796/","study_design":null,"title":"Making the Case for the Accelerated Withdrawal of Aducanumab","title_match":true,"year":2022},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/aducanumab-marketed-as-aduhelm-approval-is-likely-based-on-34657891","doi":"10.3233/jad-215275","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"34657891","source_url":"https://pubmed.ncbi.nlm.nih.gov/34657891/","study_design":null,"title":"Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data","title_match":true,"year":2021},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/accelerated-approval-of-aducanumab-where-do-we-stand-now-34595939","doi":"10.1177/10600280211050405","journal":"The Annals of pharmacotherapy","n_participants":null,"pmid":"34595939","source_url":"https://pubmed.ncbi.nlm.nih.gov/34595939/","study_design":null,"title":"Accelerated Approval of Aducanumab: Where Do We Stand Now?","title_match":true,"year":2022},{"alzhub_score":34,"alzhub_url":"https://alzhub.org/study/how-promising-are-the-latest-monoclonal-antibodies-targeting-amyloid-38193477","doi":"10.1080/14728214.2024.2304059","journal":"Expert opinion on emerging drugs","n_participants":null,"pmid":"38193477","source_url":"https://pubmed.ncbi.nlm.nih.gov/38193477/","study_design":null,"title":"How promising are the latest monoclonal antibodies targeting amyloid-\u03b2 for the treatment of early Alzheimer's disease?","title_match":false,"year":2024},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/biomarkers-as-endpoints-in-clinical-trials-for-alzheimer-s-disease-38669547","doi":"10.3233/jad-240008","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"38669547","source_url":"https://pubmed.ncbi.nlm.nih.gov/38669547/","study_design":"clinical trial","title":"Biomarkers as Endpoints in Clinical Trials for Alzheimer's Disease","title_match":false,"year":2024},{"alzhub_score":33,"alzhub_url":"https://alzhub.org/study/commentary-aducanumab-related-aria-paean-or-lament-35543641","doi":"10.1097/rlu.0000000000004252","journal":"Clinical nuclear medicine","n_participants":null,"pmid":"35543641","source_url":"https://pubmed.ncbi.nlm.nih.gov/35543641/","study_design":null,"title":"Commentary: Aducanumab-Related ARIA: Paean or Lament?","title_match":true,"year":2022},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/orally-administered-benzofuran-derivative-disaggregated-a-plaques-and-33332107","doi":"10.1021/acschemneuro.0c00606","journal":"ACS chemical neuroscience","n_participants":null,"pmid":"33332107","source_url":"https://pubmed.ncbi.nlm.nih.gov/33332107/","study_design":null,"title":"Orally Administered Benzofuran Derivative Disaggregated A\u03b2 Plaques and Oligomers in the Brain of 5XFAD Alzheimer Transgenic Mouse","title_match":false,"year":2021},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/practical-considerations-in-the-administration-of-aducanumab-for-the-35733944","doi":"10.1212/cpj.0000000000001144","journal":"Neurology. Clinical practice","n_participants":null,"pmid":"35733944","source_url":"https://pubmed.ncbi.nlm.nih.gov/35733944/","study_design":null,"title":"Practical Considerations in the Administration of Aducanumab for the Neurologist","title_match":true,"year":2022},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/aducanumab-related-amyloid-related-imaging-abnormalities-paean-or-35452007","doi":"10.1097/rlu.0000000000004250","journal":"Clinical nuclear medicine","n_participants":null,"pmid":"35452007","source_url":"https://pubmed.ncbi.nlm.nih.gov/35452007/","study_design":null,"title":"Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?","title_match":true,"year":2022},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/antiamyloid-treatment-for-dementia-concerns-outweigh-hopes-40511512","doi":"10.1097/yco.0000000000001021","journal":"Current opinion in psychiatry","n_participants":null,"pmid":"40511512","source_url":"https://pubmed.ncbi.nlm.nih.gov/40511512/","study_design":null,"title":"Antiamyloid treatment for dementia: concerns outweigh hopes","title_match":false,"year":2025},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/the-future-of-alzheimer-disease-immunotherapies-in-saudi-arabia-37045461","doi":"10.17712/nsj.2023.2.20220133","journal":"Neurosciences (Riyadh, Saudi Arabia)","n_participants":null,"pmid":"37045461","source_url":"https://pubmed.ncbi.nlm.nih.gov/37045461/","study_design":null,"title":"The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology","title_match":false,"year":2023},{"alzhub_score":32,"alzhub_url":"https://alzhub.org/study/re-aducanumab-related-aria-paean-or-lament-36607365","doi":"10.1097/rlu.0000000000004490","journal":"Clinical nuclear medicine","n_participants":null,"pmid":"36607365","source_url":"https://pubmed.ncbi.nlm.nih.gov/36607365/","study_design":null,"title":"Re: Aducanumab-Related ARIA: Paean or Lament?","title_match":true,"year":2023},{"alzhub_score":30,"alzhub_url":"https://alzhub.org/study/the-differential-diagnosis-and-treatment-of-mild-cognitive-impairment-36576369","doi":"10.4088/jcp.bg21120com4","journal":"The Journal of clinical psychiatry","n_participants":null,"pmid":"36576369","source_url":"https://pubmed.ncbi.nlm.nih.gov/36576369/","study_design":null,"title":"The Differential Diagnosis and Treatment of Mild Cognitive Impairment and Alzheimer Disease","title_match":false,"year":2022},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/a-time-to-event-exposure-response-model-for-amyloid-related-imaging-35285968","doi":"10.1002/jcph.2047","journal":"Journal of clinical pharmacology","n_participants":3251,"pmid":"35285968","source_url":"https://pubmed.ncbi.nlm.nih.gov/35285968/","study_design":"clinical trial","title":"A Time-to-Event Exposure-Response Model for Amyloid-Related Imaging Abnormalities Following Administration of Aducanumab to Subjects With Early Alzheimer Disease","title_match":true,"year":2022},{"alzhub_score":30,"alzhub_url":"https://alzhub.org/study/alzheimer-s-trials-a-cul-de-sac-with-no-end-in-sight-34313409","doi":"10.17219/acem/139501","journal":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","n_participants":null,"pmid":"34313409","source_url":"https://pubmed.ncbi.nlm.nih.gov/34313409/","study_design":null,"title":"Alzheimer's trials: A cul-de-sac with no end in sight","title_match":false,"year":2021},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/etiology-risk-factors-treatments-and-current-status-of-alzheimer-s-36256566","doi":"10.24875/gmm.m22000681","journal":"Gaceta medica de Mexico","n_participants":null,"pmid":"36256566","source_url":"https://pubmed.ncbi.nlm.nih.gov/36256566/","study_design":null,"title":"Etiology, risk factors, treatments and current status of Alzheimer's disease in Mexico","title_match":false,"year":2022},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/aducanumab-and-alzheimer-s-disease-a-critical-reflection-34263875","doi":"10.1701/3638.36183","journal":"Recenti progressi in medicina","n_participants":null,"pmid":"34263875","source_url":"https://pubmed.ncbi.nlm.nih.gov/34263875/","study_design":"clinical trial","title":"[Aducanumab and Alzheimer's disease: a critical reflection.]","title_match":true,"year":2021},{"alzhub_score":54,"alzhub_url":"https://alzhub.org/study/clinicopathologic-evaluation-of-amyloid-clearance-in-alzheimer-disease-42437499","doi":"10.1001/jama.2026.13058","journal":"JAMA","n_participants":null,"pmid":"42437499","source_url":"https://pubmed.ncbi.nlm.nih.gov/42437499/","study_design":"longitudinal study","title":"Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease","title_match":false,"year":2026},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/incidence-of-amyloid-related-imaging-abnormalities-and-health-41885326","doi":"10.18553/jmcp.2026.32.4.470","journal":"Journal of managed care & specialty pharmacy","n_participants":240,"pmid":"41885326","source_url":"https://pubmed.ncbi.nlm.nih.gov/41885326/","study_design":null,"title":"Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study","title_match":false,"year":2026},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/acquired-risk-factors-that-influence-risk-for-dementia-and-possibly-38986163","doi":null,"journal":"South Dakota medicine : the journal of the South Dakota State Medical Association","n_participants":null,"pmid":"38986163","source_url":"https://pubmed.ncbi.nlm.nih.gov/38986163/","study_design":null,"title":"Acquired Risk Factors that Influence Risk for Dementia and Possibly Alzheimer Disease","title_match":false,"year":2024},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/exploring-natural-compounds-for-alzheimer-s-disease-virtual-screening-a3b419d0","doi":"10.20944/preprints202402.0232.v1","journal":"Preprints.org","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.20944/preprints202402.0232.v1","study_design":null,"title":"Exploring Natural Compounds for Alzheimer's Disease: Virtual Screening and Docking Study with KIBRA Protein","title_match":false,"year":2024},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/the-medicolegal-and-ethical-dimensions-of-physician-prescription-35678410","doi":"10.1212/con.0000000000001164","journal":"Continuum (Minneapolis, Minn.)","n_participants":null,"pmid":"35678410","source_url":"https://pubmed.ncbi.nlm.nih.gov/35678410/","study_design":null,"title":"The Medicolegal and Ethical Dimensions of Physician Prescription Reluctance","title_match":false,"year":2022},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/alzheimer-s-disease-which-substances-are-at-present-in-phase-iii-35288774","doi":"10.1007/s00115-022-01275-5","journal":"Der Nervenarzt","n_participants":null,"pmid":"35288774","source_url":"https://pubmed.ncbi.nlm.nih.gov/35288774/","study_design":null,"title":"[Alzheimer's disease-Which substances are at present in phase III studies?]","title_match":false,"year":2022},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/novel-drug-delivery-system-a-pandora-box-for-the-manage-ment-of-f13bd11e","doi":"10.4238/0fganh12","journal":"Genetics and Molecular Research","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.4238/0fganh12","study_design":null,"title":"NOVEL DRUG DELIVERY SYSTEM: A PANDORA BOX FOR THE MANAGE MENT OF ALZHEIMER NOVEL DRUG DELIVERY IN ALZHEIMER","title_match":false,"year":2026},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/lecanemab-aducanumab-and-donanemab-bind-the-same-human-alzheimer-41435407","doi":"10.1002/alz70855_099914","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"41435407","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12726945/","study_design":null,"title":"Lecanemab, aducanumab, and donanemab bind the same human Alzheimer disease A\u03b2 aggregates at different epitopes","title_match":true,"year":2025},{"alzhub_score":30,"alzhub_url":"https://alzhub.org/study/lecanemab-en-la-enfermedad-de-alzheimer-ab04d0ab","doi":"10.22379/anc.v41i2.1938","journal":"Acta neurol\u00f3gica colombiana","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.22379/anc.v41i2.1938","study_design":null,"title":"Lecanemab en la enfermedad de Alzheimer","title_match":false,"year":2025},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-and-amyloid-related-imaging-4ee39e2d","doi":"10.5281/zenodo.22310606","journal":"Zenodo (CERN European Organization for Nuclear Research)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.22310606","study_design":"narrative review","title":"Anti-Amyloid Monoclonal Antibodies and Amyloid-Related Imaging Abnormalities in Early Alzheimer Disease","title_match":false,"year":2026},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-and-amyloid-related-imaging-95d6b60f","doi":"10.5281/zenodo.22310607","journal":"Zenodo (CERN European Organization for Nuclear Research)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.22310607","study_design":"narrative review","title":"Anti-Amyloid Monoclonal Antibodies and Amyloid-Related Imaging Abnormalities in Early Alzheimer Disease","title_match":false,"year":2026},{"alzhub_score":29,"alzhub_url":"https://alzhub.org/study/terapias-emergentes-para-la-enfermedad-de-alzheimer-revision-3c483de3","doi":"10.61368/r.s.d.h.v6i2.661","journal":"Revista Cient\u00edfica de Salud y Desarrollo Humano","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.61368/r.s.d.h.v6i2.661","study_design":null,"title":"Terapias emergentes para la enfermedad de Alzheimer: revisi\u00f3n sistem\u00e1tica de anticuerpos anti-amiloide y mecanismos alternativos","title_match":false,"year":2025},{"alzhub_score":31,"alzhub_url":"https://alzhub.org/study/lecanemab-donanemab-and-emerging-disease-modifying-therapies-for-d453d052","doi":"10.5281/zenodo.17615265","journal":"International Journal of Science and Research Archive","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.17615265","study_design":"narrative review","title":"Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in Canada","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/lecanemab-donanemab-and-emerging-disease-modifying-therapies-for-08ace6f7","doi":"10.5281/zenodo.17615266","journal":"International Journal of Science and Research Archive","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.17615266","study_design":"narrative review","title":"Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in Canada","title_match":false,"year":2025},{"alzhub_score":31,"alzhub_url":"https://alzhub.org/study/lecanemab-donanemab-and-emerging-disease-modifying-therapies-for-1b2f6657","doi":"10.30574/ijsra.2025.17.1.2929","journal":"International Journal of Science and Research Archive","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.30574/ijsra.2025.17.1.2929","study_design":"narrative review","title":"Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in Canada","title_match":false,"year":2025},{"alzhub_score":44,"alzhub_url":"https://alzhub.org/study/monoclonal-antibodies-for-treatment-alzheimer-s-disease-12954b56","doi":"10.31393/reports-vnmedical-2025-29(4)-29","journal":"Reports of Vinnytsia National Medical University","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.31393/reports-vnmedical-2025-29(4)-29","study_design":"systematic review","title":"Monoclonal antibodies for treatment Alzheimer`s disease","title_match":false,"year":2025},{"alzhub_score":31,"alzhub_url":"https://alzhub.org/study/therapeutic-monoclonal-antibodies-targeting-amyloid-beta-in-alzheimer-0a449f11","doi":"10.1186/s13064-026-00295-0","journal":"Discover Neuroscience","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1186/s13064-026-00295-0","study_design":null,"title":"Therapeutic monoclonal antibodies targeting amyloid beta in Alzheimer disease current evidence clinical outcomes limitations and future directions","title_match":false,"year":2026},{"alzhub_score":51,"alzhub_url":"https://alzhub.org/study/alzheimer-s-disease-neuroimaging-initiative-two-decades-of-pioneering-39760440","doi":"10.1002/alz.14186","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"39760440","source_url":"https://pubmed.ncbi.nlm.nih.gov/39760440/","study_design":"longitudinal study","title":"Alzheimer's Disease Neuroimaging Initiative: Two decades of pioneering Alzheimer's disease research and future directions","title_match":false,"year":2025},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/anticorpos-anti-amiloide-no-tratamento-da-doenca-de-alzheimer-uma-b2f98913","doi":"10.61411/rsc202593118","journal":"Revista Sociedade Cient\u00edfica","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.61411/rsc202593118","study_design":null,"title":"Anticorpos anti-amiloide no tratamento da Doen\u00e7a de Alzheimer: uma revis\u00e3o narrativa","title_match":false,"year":2025},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/advances-in-immunotherapy-for-alzheimer-s-disease-2020-2023-a-aa1cc3c7","doi":"10.12775/jehs.2025.80.49304","journal":"Journal of Education Health and Sport","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.12775/jehs.2025.80.49304","study_design":null,"title":"Advances in immunotherapy for Alzheimer's Disease 2020-2023 \u2013 a literature review","title_match":false,"year":2025},{"alzhub_score":26,"alzhub_url":"https://alzhub.org/study/zerebrale-amyloidangiopathie-d731ec21","doi":"10.1055/a-2572-5075","journal":"Neuroradiologie Scan","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1055/a-2572-5075","study_design":null,"title":"Zerebrale Amyloidangiopathie","title_match":false,"year":2025},{"alzhub_score":26,"alzhub_url":"https://alzhub.org/study/zerebrale-amyloidangiopathie-3d42aad1","doi":"10.1055/a-2657-2392","journal":"Geriatrie up2date","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1055/a-2657-2392","study_design":null,"title":"Zerebrale Amyloidangiopathie","title_match":false,"year":2025},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/the-social-construction-of-aduhelm-in-the-context-of-pharmaceutical-41561789","doi":"10.3389/fsoc.2025.1636160","journal":"Frontiers in Sociology","n_participants":null,"pmid":"41561789","source_url":"https://pubmed.ncbi.nlm.nih.gov/41561789/","study_design":null,"title":"The social construction of Aduhelm in the context of pharmaceutical ambiguity: exploring narratives from informal caregivers, medical professionals, and redditors on r/Alzheimers","title_match":true,"year":2026},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/polymer-engineered-a-degrading-proteases-via-photo-atrp-for-alzheimer-48774eb9","doi":"10.11134/btp.3s.2025.73","journal":"Eurasian journal of applied biotechnology","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.11134/btp.3s.2025.73","study_design":null,"title":"Polymer-Engineered A\u03b2-Degrading Proteases via Photo-ATRP for Alzheimer's Disease Therapeutics","title_match":false,"year":2025},{"alzhub_score":34,"alzhub_url":"https://alzhub.org/study/alzheimers-disease-basics-we-all-should-know-40639927","doi":"10.1080/01616412.2025.2529560","journal":"Neurological Research","n_participants":null,"pmid":"40639927","source_url":"https://pubmed.ncbi.nlm.nih.gov/40639927/","study_design":null,"title":"Alzheimer\u2019s disease basics: we all should know","title_match":false,"year":2025},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/drug-drug-interaction-signals-between-anti-amyloid-antibodies-and-ba303595","doi":"10.64898/2026.09.08.26362402","journal":"medRxiv (preprint)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.64898/2026.09.08.26362402","study_design":null,"title":"Drug-Drug Interaction Signals Between Anti-Amyloid-\u03b2 Antibodies and Antithrombotic Drugs for Amyloid-Related Imaging Abnormalities and Intracranial Hemorrhage: A FAERS Disproportionality Analysis","title_match":false,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/alzheimer-s-and-aducanumab-unjust-profits-and-false-hopes-34156732","doi":"10.1002/hast.1264","journal":"The Hastings Center report","n_participants":null,"pmid":"34156732","source_url":"https://pubmed.ncbi.nlm.nih.gov/34156732/","study_design":null,"title":"Alzheimer's and Aducanumab: Unjust Profits and False Hopes","title_match":true,"year":2021},{"alzhub_score":60,"alzhub_url":"https://alzhub.org/study/the-antibody-aducanumab-reduces-a-plaques-in-alzheimers-disease-27582220","doi":"10.1038/nature19323","journal":"Nature","n_participants":null,"pmid":"27582220","source_url":"https://pubmed.ncbi.nlm.nih.gov/27582220/","study_design":null,"title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","title_match":true,"year":2016},{"alzhub_score":61,"alzhub_url":"https://alzhub.org/study/the-amyloid-hypothesis-of-alzheimer-s-disease-at-25-years-27025652","doi":"10.15252/emmm.201606210","journal":"EMBO Molecular Medicine","n_participants":null,"pmid":"27025652","source_url":"https://pubmed.ncbi.nlm.nih.gov/27025652/","study_design":null,"title":"The amyloid hypothesis of Alzheimer's disease at 25 years","title_match":false,"year":2016},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/a-comparative-study-of-the-effects-of-aducanumab-and-scanning-a9983515","doi":"10.1101/2021.01.04.425327","journal":"Alzheimer's research & therapy","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1101/2021.01.04.425327","study_design":null,"title":"A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease","title_match":true,"year":2021},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/aducanumab-gantenerumab-ban2401-and-alz-801-the-first-wave-of-amyloid-32787971","doi":"10.1186/s13195-020-00663-w","journal":"Alzheimer's research & therapy","n_participants":null,"pmid":"32787971","source_url":"https://pubmed.ncbi.nlm.nih.gov/32787971/","study_design":"clinical trial","title":"Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval","title_match":true,"year":2020},{"alzhub_score":81,"alzhub_url":"https://alzhub.org/study/the-fda-approved-anti-amyloid-monoclonal-antibodies-for-the-treatment-38017568","doi":"10.1186/s40001-023-01512-w","journal":"European journal of medical research","n_participants":4471,"pmid":"38017568","source_url":"https://pubmed.ncbi.nlm.nih.gov/38017568/","study_design":"systematic review","title":"The FDA-approved anti-amyloid-\u03b2 monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials","title_match":false,"year":2023},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-for-the-treatment-of-alzheimer-s-37955845","doi":"10.1007/s40259-023-00633-2","journal":"BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy","n_participants":null,"pmid":"37955845","source_url":"https://pubmed.ncbi.nlm.nih.gov/37955845/","study_design":null,"title":"Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease","title_match":false,"year":2024},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/ultrasound-blood-brain-barrier-opening-and-aducanumab-in-alzheimer-s-38169490","doi":"10.1056/nejmoa2308719","journal":"The New England journal of medicine","n_participants":null,"pmid":"38169490","source_url":"https://pubmed.ncbi.nlm.nih.gov/38169490/","study_design":null,"title":"Ultrasound Blood-Brain Barrier Opening and Aducanumab in Alzheimer's Disease","title_match":true,"year":2024},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/recent-advances-in-alzheimer-s-disease-mechanisms-clinical-trials-and-39174535","doi":"10.1038/s41392-024-01911-3","journal":"Signal transduction and targeted therapy","n_participants":null,"pmid":"39174535","source_url":"https://pubmed.ncbi.nlm.nih.gov/39174535/","study_design":null,"title":"Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/failure-to-demonstrate-efficacy-of-aducanumab-an-analysis-of-the-33135381","doi":"10.1002/alz.12213","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"33135381","source_url":"https://pubmed.ncbi.nlm.nih.gov/33135381/","study_design":null,"title":"Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019","title_match":true,"year":2021},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/lecanemab-aducanumab-and-gantenerumab-binding-profiles-to-different-36253511","doi":"10.1007/s13311-022-01308-6","journal":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","n_participants":null,"pmid":"36253511","source_url":"https://pubmed.ncbi.nlm.nih.gov/36253511/","study_design":null,"title":"Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease","title_match":true,"year":2023},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/structural-and-kinetic-basis-for-the-selectivity-of-aducanumab-for-29686315","doi":"10.1038/s41598-018-24501-0","journal":"Scientific reports","n_participants":null,"pmid":"29686315","source_url":"https://pubmed.ncbi.nlm.nih.gov/29686315/","study_design":"clinical trial","title":"Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2","title_match":true,"year":2018},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/the-impact-of-systemic-inflammation-on-alzheimer-s-disease-pathology-35069578","doi":"10.3389/fimmu.2021.796867","journal":"Frontiers in immunology","n_participants":null,"pmid":"35069578","source_url":"https://pubmed.ncbi.nlm.nih.gov/35069578/","study_design":null,"title":"The Impact of Systemic Inflammation on Alzheimer's Disease Pathology","title_match":false,"year":2021},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/aducanumab-appropriate-use-recommendations-34585212","doi":"10.14283/jpad.2021.41","journal":"The journal of prevention of Alzheimer's disease","n_participants":null,"pmid":"34585212","source_url":"https://pubmed.ncbi.nlm.nih.gov/34585212/","study_design":null,"title":"Aducanumab: Appropriate Use Recommendations","title_match":true,"year":2021},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/aducanumab-first-approval-34324167","doi":"10.1007/s40265-021-01569-z","journal":"Drugs","n_participants":null,"pmid":"34324167","source_url":"https://pubmed.ncbi.nlm.nih.gov/34324167/","study_design":null,"title":"Aducanumab: First Approval","title_match":true,"year":2021},{"alzhub_score":60,"alzhub_url":"https://alzhub.org/study/past-present-and-future-of-therapeutic-strategies-against-amyloid-34687956","doi":"10.1016/j.arr.2021.101496","journal":"Ageing research reviews","n_participants":null,"pmid":"34687956","source_url":"https://pubmed.ncbi.nlm.nih.gov/34687956/","study_design":null,"title":"Past, present and future of therapeutic strategies against amyloid-\u03b2 peptides in Alzheimer's disease: a systematic review","title_match":false,"year":2021},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/the-path-forward-in-alzheimer-s-disease-therapeutics-reevaluating-the-31706733","doi":"10.1016/j.jalz.2019.09.075","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"31706733","source_url":"https://pubmed.ncbi.nlm.nih.gov/31706733/","study_design":"clinical trial","title":"The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis","title_match":false,"year":2020},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/impact-of-anti-amyloid-monoclonal-antibodies-on-the-pathology-and-35493943","doi":"10.3389/fnagi.2022.870517","journal":"Frontiers in aging neuroscience","n_participants":null,"pmid":"35493943","source_url":"https://pubmed.ncbi.nlm.nih.gov/35493943/","study_design":null,"title":"Impact of Anti-amyloid-\u03b2 Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab","title_match":true,"year":2022},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-are-transformative-treatments-that-37060386","doi":"10.1007/s40265-023-01858-9","journal":"Drugs","n_participants":null,"pmid":"37060386","source_url":"https://pubmed.ncbi.nlm.nih.gov/37060386/","study_design":null,"title":"Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics","title_match":false,"year":2023},{"alzhub_score":84,"alzhub_url":"https://alzhub.org/study/effects-of-monoclonal-antibodies-against-amyloid-on-clinical-and-33831607","doi":"10.1016/j.arr.2021.101339","journal":"Ageing research reviews","n_participants":12585,"pmid":"33831607","source_url":"https://pubmed.ncbi.nlm.nih.gov/33831607/","study_design":"meta-analysis","title":"Effects of monoclonal antibodies against amyloid-\u03b2 on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease","title_match":false,"year":2021},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/the-neuroprotective-effects-of-glucagon-like-peptide-1-in-alzheimer-s-36117625","doi":"10.3389/fnins.2022.970925","journal":"Frontiers in neuroscience","n_participants":null,"pmid":"36117625","source_url":"https://pubmed.ncbi.nlm.nih.gov/36117625/","study_design":null,"title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review","title_match":false,"year":2022},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/neurotoxic-soluble-amyloid-oligomers-drive-alzheimer-s-pathogenesis-34198582","doi":"10.3390/ijms22126355","journal":"International journal of molecular sciences","n_participants":null,"pmid":"34198582","source_url":"https://pubmed.ncbi.nlm.nih.gov/34198582/","study_design":null,"title":"Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression","title_match":false,"year":2021},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/immunotherapy-for-alzheimer-s-disease-targeting-amyloid-and-beyond-35300725","doi":"10.1186/s40035-022-00292-3","journal":"Translational neurodegeneration","n_participants":null,"pmid":"35300725","source_url":"https://pubmed.ncbi.nlm.nih.gov/35300725/","study_design":null,"title":"Immunotherapy for Alzheimer's disease: targeting \u03b2-amyloid and beyond","title_match":false,"year":2022},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/alzheimer-s-disease-key-insights-from-two-decades-of-clinical-trial-35342092","doi":"10.3233/jad-215699","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"35342092","source_url":"https://pubmed.ncbi.nlm.nih.gov/35342092/","study_design":null,"title":"Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures","title_match":false,"year":2022},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/kinetic-fingerprints-differentiate-the-mechanisms-of-action-of-anti-a-32989305","doi":"10.1038/s41594-020-0505-6","journal":"Nature structural & molecular biology","n_participants":null,"pmid":"32989305","source_url":"https://pubmed.ncbi.nlm.nih.gov/32989305/","study_design":null,"title":"Kinetic fingerprints differentiate the mechanisms of action of anti-A\u03b2 antibodies","title_match":false,"year":2020},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/therapeutic-approach-to-alzheimer-s-disease-current-treatments-and-35745693","doi":"10.3390/pharmaceutics14061117","journal":"Pharmaceutics","n_participants":null,"pmid":"35745693","source_url":"https://pubmed.ncbi.nlm.nih.gov/35745693/","study_design":null,"title":"Therapeutic Approach to Alzheimer's Disease: Current Treatments and New Perspectives","title_match":false,"year":2022},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/recent-advances-on-drug-development-and-emerging-therapeutic-agents-34181171","doi":"10.1007/s11033-021-06512-9","journal":"Molecular biology reports","n_participants":null,"pmid":"34181171","source_url":"https://pubmed.ncbi.nlm.nih.gov/34181171/","study_design":null,"title":"Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease","title_match":false,"year":2021},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/aducanumab-appropriate-use-recommendations-update-35542993","doi":"10.14283/jpad.2022.34","journal":"The journal of prevention of Alzheimer's disease","n_participants":null,"pmid":"35542993","source_url":"https://pubmed.ncbi.nlm.nih.gov/35542993/","study_design":null,"title":"Aducanumab: Appropriate Use Recommendations Update","title_match":true,"year":2022},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/aducanumab-evidence-from-clinical-trial-data-and-controversies-34650610","doi":"10.7573/dic.2021-7-3","journal":"Drugs in context","n_participants":null,"pmid":"34650610","source_url":"https://pubmed.ncbi.nlm.nih.gov/34650610/","study_design":null,"title":"Aducanumab: evidence from clinical trial data and controversies","title_match":true,"year":2021},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/detection-and-management-of-amyloid-related-imaging-abnormalities-in-35542992","doi":"10.14283/jpad.2022.21","journal":"The journal of prevention of Alzheimer's disease","n_participants":null,"pmid":"35542992","source_url":"https://pubmed.ncbi.nlm.nih.gov/35542992/","study_design":null,"title":"Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy","title_match":false,"year":2022},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/reimagining-cholinergic-therapy-for-alzheimer-s-disease-35289363","doi":"10.1093/brain/awac096","journal":"Brain : a journal of neurology","n_participants":null,"pmid":"35289363","source_url":"https://pubmed.ncbi.nlm.nih.gov/35289363/","study_design":null,"title":"Reimagining cholinergic therapy for Alzheimer's disease","title_match":false,"year":2022},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/alzheimer-s-disease-targeting-the-glutamatergic-system-32048098","doi":"10.1007/s10522-020-09860-4","journal":"Biogerontology","n_participants":null,"pmid":"32048098","source_url":"https://pubmed.ncbi.nlm.nih.gov/32048098/","study_design":null,"title":"Alzheimer's disease: targeting the glutamatergic system","title_match":false,"year":2020},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/role-of-aducanumab-in-the-treatment-of-alzheimer-s-disease-challenges-35611326","doi":"10.2147/cia.s325026","journal":"Clinical interventions in aging","n_participants":null,"pmid":"35611326","source_url":"https://pubmed.ncbi.nlm.nih.gov/35611326/","study_design":"clinical trial","title":"Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities","title_match":true,"year":2022},{"alzhub_score":53,"alzhub_url":"https://alzhub.org/study/first-in-human-double-blind-placebo-controlled-single-dose-escalation-29067304","doi":"10.1016/j.trci.2016.06.002","journal":"Alzheimer's & dementia (New York, N. Y.)","n_participants":null,"pmid":"29067304","source_url":"https://pubmed.ncbi.nlm.nih.gov/29067304/","study_design":null,"title":"First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease","title_match":true,"year":2016},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/current-and-future-therapeutic-strategies-for-alzheimer-s-disease-an-37600514","doi":"10.3389/fnagi.2023.1206572","journal":"Frontiers in aging neuroscience","n_participants":null,"pmid":"37600514","source_url":"https://pubmed.ncbi.nlm.nih.gov/37600514/","study_design":null,"title":"Current and future therapeutic strategies for Alzheimer's disease: an overview of drug development bottlenecks","title_match":false,"year":2023},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/micrornas-in-alzheimer-s-disease-potential-diagnostic-markers-and-35177290","doi":"10.1016/j.biopha.2022.112681","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","n_participants":null,"pmid":"35177290","source_url":"https://pubmed.ncbi.nlm.nih.gov/35177290/","study_design":null,"title":"MicroRNAs in Alzheimer's disease: Potential diagnostic markers and therapeutic targets","title_match":false,"year":2022},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/anti-amyloid-immunotherapies-for-alzheimer-s-disease-a-2023-clinical-37490245","doi":"10.1007/s13311-023-01405-0","journal":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","n_participants":null,"pmid":"37490245","source_url":"https://pubmed.ncbi.nlm.nih.gov/37490245/","study_design":"clinical trial","title":"Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update","title_match":false,"year":2023},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/second-generation-anti-amyloid-monoclonal-antibodies-for-alzheimer-s-39865265","doi":"10.1186/s40035-025-00465-w","journal":"Translational neurodegeneration","n_participants":null,"pmid":"39865265","source_url":"https://pubmed.ncbi.nlm.nih.gov/39865265/","study_design":null,"title":"Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: current landscape and future perspectives","title_match":false,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/disease-modifying-therapies-for-alzheimer-s-disease-more-questions-35229269","doi":"10.1007/s13311-022-01201-2","journal":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","n_participants":null,"pmid":"35229269","source_url":"https://pubmed.ncbi.nlm.nih.gov/35229269/","study_design":null,"title":"Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers","title_match":false,"year":2022},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/risk-factors-in-developing-amyloid-related-imaging-abnormalities-aria-38312931","doi":"10.3389/fnins.2024.1326784","journal":"Frontiers in neuroscience","n_participants":null,"pmid":"38312931","source_url":"https://pubmed.ncbi.nlm.nih.gov/38312931/","study_design":null,"title":"Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications","title_match":false,"year":2024},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/clinical-development-of-aducanumab-an-anti-a-human-monoclonal-29181491","doi":"10.14283/jpad.2017.39","journal":"The journal of prevention of Alzheimer's disease","n_participants":196,"pmid":"29181491","source_url":"https://pubmed.ncbi.nlm.nih.gov/29181491/","study_design":null,"title":"Clinical Development of Aducanumab, an Anti-A\u03b2 Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease","title_match":true,"year":2017},{"alzhub_score":59,"alzhub_url":"https://alzhub.org/study/efficacy-and-safety-of-anti-amyloid-immunotherapy-for-alzheimer-s-29296624","doi":"10.1002/acn3.469","journal":"Annals of clinical and translational neurology","n_participants":5141,"pmid":"29296624","source_url":"https://pubmed.ncbi.nlm.nih.gov/29296624/","study_design":null,"title":"Efficacy and safety of anti-amyloid- \u03b2 immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis","title_match":false,"year":2017},{"alzhub_score":79,"alzhub_url":"https://alzhub.org/study/efficacy-and-safety-of-anti-amyloid-monoclonal-antibodies-in-current-37423541","doi":"10.1016/j.arr.2023.102012","journal":"Ageing research reviews","n_participants":14980,"pmid":"37423541","source_url":"https://pubmed.ncbi.nlm.nih.gov/37423541/","study_design":"meta-analysis","title":"Efficacy and safety of anti-amyloid-\u03b2 monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis","title_match":false,"year":2023},{"alzhub_score":71,"alzhub_url":"https://alzhub.org/study/high-clearance-anti-amyloid-immunotherapies-in-alzheimer-s-disease-36184326","doi":"10.1016/j.neurol.2022.06.012","journal":"Revue neurologique","n_participants":null,"pmid":"36184326","source_url":"https://pubmed.ncbi.nlm.nih.gov/36184326/","study_design":"meta-analysis","title":"High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects","title_match":false,"year":2022},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/amyloid-beta-antibody-binding-to-cerebral-amyloid-angiopathy-fibrils-38740836","doi":"10.1038/s41598-024-61691-2","journal":"Scientific reports","n_participants":null,"pmid":"38740836","source_url":"https://pubmed.ncbi.nlm.nih.gov/38740836/","study_design":null,"title":"Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities","title_match":false,"year":2024},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-aria-in-immunotherapy-trials-27031492","doi":"10.3233/jad-160122","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"27031492","source_url":"https://pubmed.ncbi.nlm.nih.gov/27031492/","study_design":"clinical trial","title":"Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?","title_match":false,"year":2016},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/aducanumab-making-a-comeback-in-alzheimer-s-disease-an-old-wine-in-a-35231697","doi":"10.1016/j.biopha.2022.112746","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","n_participants":null,"pmid":"35231697","source_url":"https://pubmed.ncbi.nlm.nih.gov/35231697/","study_design":null,"title":"\"Aducanumab\" making a comeback in Alzheimer's disease: An old wine in a new bottle","title_match":true,"year":2022},{"alzhub_score":84,"alzhub_url":"https://alzhub.org/study/comparative-efficacy-and-safety-of-monoclonal-antibodies-for-38429615","doi":"10.1007/s40263-024-01067-2","journal":"CNS drugs","n_participants":21087,"pmid":"38429615","source_url":"https://pubmed.ncbi.nlm.nih.gov/38429615/","study_design":"meta-analysis","title":"Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis","title_match":false,"year":2024},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-for-alzheimer-s-disease-evidence-41003140","doi":"10.3390/jpm15090437","journal":"Journal of personalized medicine","n_participants":null,"pmid":"41003140","source_url":"https://pubmed.ncbi.nlm.nih.gov/41003140/","study_design":null,"title":"Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease: Evidence, ARIA Risk, and Precision Patient Selection","title_match":false,"year":2025},{"alzhub_score":88,"alzhub_url":"https://alzhub.org/study/trailblazer-alz-4-a-phase-3-trial-comparing-donanemab-with-aducanumab-40390253","doi":"10.1002/alz.70293","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":148,"pmid":"40390253","source_url":"https://pubmed.ncbi.nlm.nih.gov/40390253/","study_design":"clinical trial","title":"TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease","title_match":true,"year":2025},{"alzhub_score":83,"alzhub_url":"https://alzhub.org/study/results-from-the-long-term-extension-of-prime-a-randomized-phase-1b-38567735","doi":"10.1002/alz.13755","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"38567735","source_url":"https://pubmed.ncbi.nlm.nih.gov/38567735/","study_design":null,"title":"Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab","title_match":true,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/a-combined-physiologically-based-pharmacokinetic-and-quantitative-36632701","doi":"10.1002/psp4.12912","journal":"CPT: pharmacometrics & systems pharmacology","n_participants":null,"pmid":"36632701","source_url":"https://pubmed.ncbi.nlm.nih.gov/36632701/","study_design":null,"title":"A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease","title_match":false,"year":2023},{"alzhub_score":67,"alzhub_url":"https://alzhub.org/study/application-of-meta-analysis-to-evaluate-relationships-among-aria-e-35320578","doi":"10.1007/s43441-022-00390-4","journal":"Therapeutic innovation & regulatory science","n_participants":null,"pmid":"35320578","source_url":"https://pubmed.ncbi.nlm.nih.gov/35320578/","study_design":"meta-analysis","title":"Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease","title_match":false,"year":2022},{"alzhub_score":83,"alzhub_url":"https://alzhub.org/study/the-efficacy-and-safety-of-anti-amyloid-monoclonal-antibody-versus-40316479","doi":"10.1016/j.tjpad.2025.100195","journal":"The journal of prevention of Alzheimer's disease","n_participants":8010,"pmid":"40316479","source_url":"https://pubmed.ncbi.nlm.nih.gov/40316479/","study_design":"randomized controlled trial","title":"The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-aria-diagnosis-management-and-38939962","doi":"10.1002/acn3.52042","journal":"Annals of clinical and translational neurology","n_participants":null,"pmid":"38939962","source_url":"https://pubmed.ncbi.nlm.nih.gov/38939962/","study_design":null,"title":"Amyloid-related imaging abnormalities (ARIA): diagnosis, management, and care in the setting of amyloid-modifying therapy","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/disease-modeling-and-model-based-meta-analyses-to-define-a-new-35100444","doi":"10.1002/cpt.2535","journal":"Clinical pharmacology and therapeutics","n_participants":null,"pmid":"35100444","source_url":"https://pubmed.ncbi.nlm.nih.gov/35100444/","study_design":"open-label trial","title":"Disease Modeling and Model-Based Meta-Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer's Disease","title_match":false,"year":2022},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/recent-advances-in-antibody-therapy-for-alzheimer-s-disease-focus-on-40650049","doi":"10.3390/ijms26136271","journal":"International journal of molecular sciences","n_participants":null,"pmid":"40650049","source_url":"https://pubmed.ncbi.nlm.nih.gov/40650049/","study_design":null,"title":"Recent Advances in Antibody Therapy for Alzheimer's Disease: Focus on Bispecific Antibodies","title_match":false,"year":2025},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/vascular-considerations-for-amyloid-immunotherapy-36269539","doi":"10.1007/s11910-022-01235-1","journal":"Current neurology and neuroscience reports","n_participants":null,"pmid":"36269539","source_url":"https://pubmed.ncbi.nlm.nih.gov/36269539/","study_design":null,"title":"Vascular Considerations for Amyloid Immunotherapy","title_match":false,"year":2022},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/aducanumab-for-alzheimer-s-disease-summarized-data-from-emerge-engage-35879846","doi":"10.4140/tcp.n.2022.329","journal":"The Senior care pharmacist","n_participants":null,"pmid":"35879846","source_url":"https://pubmed.ncbi.nlm.nih.gov/35879846/","study_design":"clinical trial","title":"Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies","title_match":true,"year":2022},{"alzhub_score":72,"alzhub_url":"https://alzhub.org/study/a-systematic-review-of-the-efficacy-and-safety-of-anti-amyloid-40621323","doi":"10.7759/cureus.85377","journal":"Cureus","n_participants":null,"pmid":"40621323","source_url":"https://pubmed.ncbi.nlm.nih.gov/40621323/","study_design":"systematic review","title":"A Systematic Review of the Efficacy and Safety of Anti-amyloid Monoclonal Antibodies in Alzheimer's Disease","title_match":false,"year":2025},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/initial-experiences-with-amyloid-related-imaging-abnormalities-in-37874098","doi":"10.14283/jpad.2023.96","journal":"The journal of prevention of Alzheimer's disease","n_participants":24,"pmid":"37874098","source_url":"https://pubmed.ncbi.nlm.nih.gov/37874098/","study_design":null,"title":"Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval","title_match":true,"year":2023},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/a-real-world-pharmacovigilance-study-of-adverse-drug-reactions-40290431","doi":"10.3389/fphar.2025.1561020","journal":"Frontiers in pharmacology","n_participants":null,"pmid":"40290431","source_url":"https://pubmed.ncbi.nlm.nih.gov/40290431/","study_design":null,"title":"A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases","title_match":true,"year":2025},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/quantitative-systems-pharmacology-based-exploration-of-relevant-anti-38774587","doi":"10.1002/trc2.12474","journal":"Alzheimer's & dementia (New York, N. Y.)","n_participants":null,"pmid":"38774587","source_url":"https://pubmed.ncbi.nlm.nih.gov/38774587/","study_design":null,"title":"Quantitative systems pharmacology-based exploration of relevant anti-amyloid therapy challenges in clinical practice","title_match":false,"year":2024},{"alzhub_score":59,"alzhub_url":"https://alzhub.org/study/comparison-of-safety-of-lecanemab-and-aducanumab-a-real-world-40520157","doi":"10.3389/fphar.2025.1593989","journal":"Frontiers in pharmacology","n_participants":1409,"pmid":"40520157","source_url":"https://pubmed.ncbi.nlm.nih.gov/40520157/","study_design":null,"title":"Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system","title_match":true,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/more-failure-with-solanezumab-this-time-in-preclinical-alzheimer-s-38414336","doi":"10.1080/14712598.2024.2325551","journal":"Expert opinion on biological therapy","n_participants":null,"pmid":"38414336","source_url":"https://pubmed.ncbi.nlm.nih.gov/38414336/","study_design":"clinical trial","title":"More failure with solanezumab - this time in preclinical Alzheimer's disease","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/alzheimer-s-disease-and-epilepsy-shared-neuropathology-guides-current-37936917","doi":"10.3389/fneur.2023.1241339","journal":"Frontiers in neurology","n_participants":null,"pmid":"37936917","source_url":"https://pubmed.ncbi.nlm.nih.gov/37936917/","study_design":null,"title":"Alzheimer's disease and epilepsy: shared neuropathology guides current and future treatment strategies","title_match":false,"year":2023},{"alzhub_score":84,"alzhub_url":"https://alzhub.org/study/japanese-subgroup-analyses-from-emerge-and-engage-phase-3-clinical-39350371","doi":"10.14283/jpad.2024.106","journal":"The journal of prevention of Alzheimer's disease","n_participants":121,"pmid":"39350371","source_url":"https://pubmed.ncbi.nlm.nih.gov/39350371/","study_design":"clinical trial","title":"Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease","title_match":true,"year":2024},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/fda-approved-passive-immunization-treatments-against-a-in-alzheimer-s-41596530","doi":"10.3390/ijms27020883","journal":"International journal of molecular sciences","n_participants":null,"pmid":"41596530","source_url":"https://pubmed.ncbi.nlm.nih.gov/41596530/","study_design":null,"title":"FDA-Approved Passive Immunization Treatments Against A\u03b2 in Alzheimer's Disease: Where Are We Now?","title_match":false,"year":2026},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/profiling-aducanumab-as-a-treatment-option-for-alzheimer-s-disease-an-39291991","doi":"10.1080/14737175.2024.2402058","journal":"Expert review of neurotherapeutics","n_participants":null,"pmid":"39291991","source_url":"https://pubmed.ncbi.nlm.nih.gov/39291991/","study_design":null,"title":"Profiling aducanumab as a treatment option for Alzheimer's disease: an overview of efficacy, safety and tolerability","title_match":true,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibody-therapies-in-alzheimer-s-disease-a-41077117","doi":"10.1016/j.neuroscience.2025.10.011","journal":"Neuroscience","n_participants":null,"pmid":"41077117","source_url":"https://pubmed.ncbi.nlm.nih.gov/41077117/","study_design":null,"title":"Anti-amyloid monoclonal antibody therapies in Alzheimer's disease - a scoping review","title_match":false,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/plasma-neurofilament-l-to-amyloid-42-ratio-in-differentiating-34741884","doi":"10.1016/j.ajp.2021.102914","journal":"Asian journal of psychiatry","n_participants":null,"pmid":"34741884","source_url":"https://pubmed.ncbi.nlm.nih.gov/34741884/","study_design":null,"title":"Plasma neurofilament L to amyloid \u03b242 ratio in differentiating Alzheimer's type from non-Alzheimer's dementia: A cross-sectional pilot study from India","title_match":false,"year":2021},{"alzhub_score":84,"alzhub_url":"https://alzhub.org/study/csf-biomarker-concordance-with-amyloid-pet-in-phase-3-studies-of-36795603","doi":"10.1002/alz.12919","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"36795603","source_url":"https://pubmed.ncbi.nlm.nih.gov/36795603/","study_design":"clinical trial","title":"CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab","title_match":true,"year":2023},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/passive-anti-amyloid-immunotherapy-in-alzheimer-s-disease-39549715","doi":"10.1016/s0140-6736(24)01883-x","journal":"Lancet (London, England)","n_participants":null,"pmid":"39549715","source_url":"https://pubmed.ncbi.nlm.nih.gov/39549715/","study_design":null,"title":"Passive anti-amyloid \u03b2 immunotherapy in Alzheimer's disease-opportunities and challenges","title_match":false,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/anti-amyloid-therapies-for-alzheimer-s-disease-and-the-amyloid-37833948","doi":"10.3390/ijms241914499","journal":"International journal of molecular sciences","n_participants":null,"pmid":"37833948","source_url":"https://pubmed.ncbi.nlm.nih.gov/37833948/","study_design":null,"title":"Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis","title_match":false,"year":2023},{"alzhub_score":82,"alzhub_url":"https://alzhub.org/study/comparative-efficacy-tolerability-and-acceptability-of-donanemab-38253184","doi":"10.1016/j.arr.2024.102203","journal":"Ageing research reviews","n_participants":6547,"pmid":"38253184","source_url":"https://pubmed.ncbi.nlm.nih.gov/38253184/","study_design":"meta-analysis","title":"Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis","title_match":true,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/anti-amyloid-antibodies-and-anti-tau-therapies-for-alzheimer-s-38945936","doi":"10.1248/cpb.c24-00069","journal":"Chemical & pharmaceutical bulletin","n_participants":null,"pmid":"38945936","source_url":"https://pubmed.ncbi.nlm.nih.gov/38945936/","study_design":"clinical trial","title":"Anti-amyloid-\u03b2 Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives","title_match":false,"year":2024},{"alzhub_score":70,"alzhub_url":"https://alzhub.org/study/aducanumab-for-the-treatment-of-alzheimer-s-disease-a-systematic-36775284","doi":"10.1111/psyg.12944","journal":"Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society","n_participants":null,"pmid":"36775284","source_url":"https://pubmed.ncbi.nlm.nih.gov/36775284/","study_design":"meta-analysis","title":"Aducanumab for the treatment of Alzheimer's disease: a systematic review","title_match":true,"year":2023},{"alzhub_score":46,"alzhub_url":"https://alzhub.org/study/overview-of-alzheimer-s-disease-neuroimaging-initiative-and-future-39711072","doi":"10.1002/alz.14321","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"39711072","source_url":"https://pubmed.ncbi.nlm.nih.gov/39711072/","study_design":null,"title":"Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials","title_match":false,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/lecanemab-leqembi-is-not-the-right-drug-for-patients-with-alzheimer-s-37676096","doi":"10.17219/acem/171379","journal":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","n_participants":null,"pmid":"37676096","source_url":"https://pubmed.ncbi.nlm.nih.gov/37676096/","study_design":null,"title":"Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease","title_match":false,"year":2023},{"alzhub_score":71,"alzhub_url":"https://alzhub.org/study/a-systematic-review-of-the-efficacy-and-safety-of-anti-amyloid-beta-39432414","doi":"10.1080/14712598.2024.2416947","journal":"Expert opinion on biological therapy","n_participants":null,"pmid":"39432414","source_url":"https://pubmed.ncbi.nlm.nih.gov/39432414/","study_design":null,"title":"A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer's disease","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/maximizing-the-benefit-and-managing-the-risk-of-anti-amyloid-40118715","doi":"10.1016/j.neurot.2025.e00570","journal":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","n_participants":null,"pmid":"40118715","source_url":"https://pubmed.ncbi.nlm.nih.gov/40118715/","study_design":null,"title":"Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions","title_match":false,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/imaging-spectrum-of-amyloid-related-imaging-abnormalities-associated-38249159","doi":"10.3389/fradi.2023.1305390","journal":"Frontiers in radiology","n_participants":null,"pmid":"38249159","source_url":"https://pubmed.ncbi.nlm.nih.gov/38249159/","study_design":null,"title":"Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy","title_match":true,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/donanemab-another-anti-alzheimer-s-drug-with-risk-and-uncertain-38830549","doi":"10.1016/j.arr.2024.102348","journal":"Ageing research reviews","n_participants":null,"pmid":"38830549","source_url":"https://pubmed.ncbi.nlm.nih.gov/38830549/","study_design":null,"title":"Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/anti-amyloid-antibody-therapies-for-alzheimer-s-disease-38932758","doi":"10.1007/s13139-024-00848-3","journal":"Nuclear medicine and molecular imaging","n_participants":null,"pmid":"38932758","source_url":"https://pubmed.ncbi.nlm.nih.gov/38932758/","study_design":"clinical trial","title":"Anti-amyloid Antibody Therapies for Alzheimer's Disease","title_match":false,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/monoclonal-antibody-treatments-for-alzheimer-s-disease-aducanumab-and-39726673","doi":"10.15190/d.2023.12","journal":"Discoveries (Craiova, Romania)","n_participants":null,"pmid":"39726673","source_url":"https://pubmed.ncbi.nlm.nih.gov/39726673/","study_design":null,"title":"Monoclonal Antibody Treatments for Alzheimer's Disease: Aducanumab and Lecanemab","title_match":true,"year":2023},{"alzhub_score":82,"alzhub_url":"https://alzhub.org/study/comparative-efficacy-tolerability-and-acceptability-of-aducanumab-40386876","doi":"10.1177/02698811251340901","journal":"Journal of psychopharmacology (Oxford, England)","n_participants":6918,"pmid":"40386876","source_url":"https://pubmed.ncbi.nlm.nih.gov/40386876/","study_design":"meta-analysis","title":"Comparative efficacy, tolerability, and acceptability of aducanumab, lecanemab, and donanemab with repetitive transcranial magnetic stimulation on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis","title_match":true,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/donanemab-not-two-without-a-third-37831471","doi":"10.17219/acem/172673","journal":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","n_participants":null,"pmid":"37831471","source_url":"https://pubmed.ncbi.nlm.nih.gov/37831471/","study_design":null,"title":"Donanemab: Not two without a third","title_match":false,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/aducanumab-a-look-two-years-after-its-approval-39079148","doi":"10.7705/biomedica.6967","journal":"Biomedica : revista del Instituto Nacional de Salud","n_participants":null,"pmid":"39079148","source_url":"https://pubmed.ncbi.nlm.nih.gov/39079148/","study_design":null,"title":"Aducanumab: A look two years after its approval","title_match":true,"year":2024},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/optimal-anti-amyloid-beta-therapy-for-alzheimer-s-disease-via-a-36054214","doi":"10.1371/journal.pcbi.1010481","journal":"PLoS computational biology","n_participants":null,"pmid":"36054214","source_url":"https://pubmed.ncbi.nlm.nih.gov/36054214/","study_design":null,"title":"Optimal anti-amyloid-beta therapy for Alzheimer's disease via a personalized mathematical model","title_match":false,"year":2022},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/pharmacological-interventions-in-dementia-41047647","doi":"10.11477/mf.030126030530050943","journal":"No shinkei geka. Neurological surgery","n_participants":null,"pmid":"41047647","source_url":"https://pubmed.ncbi.nlm.nih.gov/41047647/","study_design":null,"title":"[Pharmacological Interventions in Dementia]","title_match":false,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/aducanumab-anti-amyloid-immunotherapy-induces-sustained-microglial-38226975","doi":"10.1084/jem.20231363","journal":"The Journal of experimental medicine","n_participants":null,"pmid":"38226975","source_url":"https://pubmed.ncbi.nlm.nih.gov/38226975/","study_design":null,"title":"Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations","title_match":true,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/aducanumab-a-novel-anti-amyloid-monoclonal-antibody-for-the-treatment-35928986","doi":"10.52965/001c.31925","journal":"Health psychology research","n_participants":null,"pmid":"35928986","source_url":"https://pubmed.ncbi.nlm.nih.gov/35928986/","study_design":null,"title":"Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer's Disease: A Comprehensive Review","title_match":true,"year":2022},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/therapeutic-news-in-alzheimer-s-disease-soon-a-disease-modifying-35489824","doi":"10.1016/j.neurol.2022.02.456","journal":"Revue neurologique","n_participants":null,"pmid":"35489824","source_url":"https://pubmed.ncbi.nlm.nih.gov/35489824/","study_design":null,"title":"Therapeutic news in Alzheimer's disease: Soon a disease-modifying therapy?","title_match":false,"year":2022},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/alzheimer-s-amyloid-hypothesis-and-antibody-therapy-melting-glaciers-38612701","doi":"10.3390/ijms25073892","journal":"International journal of molecular sciences","n_participants":null,"pmid":"38612701","source_url":"https://pubmed.ncbi.nlm.nih.gov/38612701/","study_design":null,"title":"Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/anti-amyloid-antibody-therapy-for-alzheimer-s-disease-39370836","doi":"10.11477/mf.1416202747","journal":"Brain and nerve = Shinkei kenkyu no shinpo","n_participants":null,"pmid":"39370836","source_url":"https://pubmed.ncbi.nlm.nih.gov/39370836/","study_design":"clinical trial","title":"[Anti-Amyloid Antibody Therapy for Alzheimer's Disease]","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/multi-targeting-phytochemicals-for-alzheimer-s-disease-39815655","doi":"10.1002/ptr.8435","journal":"Phytotherapy research : PTR","n_participants":null,"pmid":"39815655","source_url":"https://pubmed.ncbi.nlm.nih.gov/39815655/","study_design":null,"title":"Multi-Targeting Phytochemicals for Alzheimer's Disease","title_match":false,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/symptomatic-amyloid-related-imaging-abnormalities-in-an-apoe-4-4-33072846","doi":"10.1002/dad2.12101","journal":"Alzheimer's & dementia (Amsterdam, Netherlands)","n_participants":null,"pmid":"33072846","source_url":"https://pubmed.ncbi.nlm.nih.gov/33072846/","study_design":null,"title":"Symptomatic amyloid-related imaging abnormalities in an APOE \u03b54/\u03b54 patient treated with aducanumab","title_match":true,"year":2020},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/passive-alzheimer-s-immunotherapy-a-promising-or-uncertain-option-37414156","doi":"10.1016/j.arr.2023.101996","journal":"Ageing research reviews","n_participants":null,"pmid":"37414156","source_url":"https://pubmed.ncbi.nlm.nih.gov/37414156/","study_design":null,"title":"Passive Alzheimer's immunotherapy: A promising or uncertain option?","title_match":false,"year":2023},{"alzhub_score":46,"alzhub_url":"https://alzhub.org/study/messenger-rna-encoded-antibody-approach-for-targeting-extracellular-38585667","doi":"10.1093/braincomms/fcae100","journal":"Brain communications","n_participants":null,"pmid":"38585667","source_url":"https://pubmed.ncbi.nlm.nih.gov/38585667/","study_design":null,"title":"Messenger RNA-encoded antibody approach for targeting extracellular and intracellular tau","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/nanobody-therapeutics-in-alzheimer-s-disease-from-molecular-41562774","doi":"10.3390/antib15010001","journal":"Antibodies (Basel, Switzerland)","n_participants":null,"pmid":"41562774","source_url":"https://pubmed.ncbi.nlm.nih.gov/41562774/","study_design":null,"title":"Nanobody Therapeutics in Alzheimer's Disease: From Molecular Mechanisms to Translational Approaches","title_match":false,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/guidelines-for-pharmacotherapy-in-alzheimer-s-disease-a-primer-on-fda-38059250","doi":"10.25259/jnrp_356_2023","journal":"Journal of neurosciences in rural practice","n_participants":null,"pmid":"38059250","source_url":"https://pubmed.ncbi.nlm.nih.gov/38059250/","study_design":null,"title":"Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs","title_match":false,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/polypharmacological-potential-of-phosphodiesterase-5-inhibitors-for-38270120","doi":"10.14336/ad.2023.1129","journal":"Aging and disease","n_participants":null,"pmid":"38270120","source_url":"https://pubmed.ncbi.nlm.nih.gov/38270120/","study_design":null,"title":"Polypharmacological Potential of Phosphodiesterase 5 Inhibitors for the Treatment of Neurocognitive Disorders","title_match":false,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/tryptamine-a-privileged-scaffold-for-the-management-of-alzheimer-s-37675624","doi":"10.1002/ddr.22111","journal":"Drug development research","n_participants":null,"pmid":"37675624","source_url":"https://pubmed.ncbi.nlm.nih.gov/37675624/","study_design":null,"title":"Tryptamine: A privileged scaffold for the management of Alzheimer's disease","title_match":false,"year":2023},{"alzhub_score":80,"alzhub_url":"https://alzhub.org/study/investigating-partially-discordant-results-in-phase-3-studies-of-36946443","doi":"10.14283/jpad.2023.6","journal":"The journal of prevention of Alzheimer's disease","n_participants":1638,"pmid":"36946443","source_url":"https://pubmed.ncbi.nlm.nih.gov/36946443/","study_design":"post-hoc analysis","title":"Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab","title_match":true,"year":2023},{"alzhub_score":54,"alzhub_url":"https://alzhub.org/study/potential-impact-of-unblinding-on-observed-treatment-effects-in-38380503","doi":"10.1002/alz.13690","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"38380503","source_url":"https://pubmed.ncbi.nlm.nih.gov/38380503/","study_design":"clinical trial","title":"Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials","title_match":false,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/assessments-of-the-value-of-new-interventions-should-include-health-35237944","doi":"10.1007/s40273-022-01131-z","journal":"PharmacoEconomics","n_participants":null,"pmid":"35237944","source_url":"https://pubmed.ncbi.nlm.nih.gov/35237944/","study_design":null,"title":"Assessments of the Value of New Interventions Should Include Health Equity Impact","title_match":false,"year":2022},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/estimated-annual-spending-on-aducanumab-in-the-us-medicare-program-35977233","doi":"10.1001/jamahealthforum.2021.4495","journal":"JAMA health forum","n_participants":null,"pmid":"35977233","source_url":"https://pubmed.ncbi.nlm.nih.gov/35977233/","study_design":"cross-sectional","title":"Estimated Annual Spending on Aducanumab in the US Medicare Program","title_match":true,"year":2022},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/the-effectiveness-and-value-of-aducanumab-for-alzheimer-s-disease-34714106","doi":"10.18553/jmcp.2021.27.11.1613","journal":"Journal of managed care & specialty pharmacy","n_participants":null,"pmid":"34714106","source_url":"https://pubmed.ncbi.nlm.nih.gov/34714106/","study_design":null,"title":"The effectiveness and value of aducanumab for Alzheimer's disease","title_match":true,"year":2021},{"alzhub_score":46,"alzhub_url":"https://alzhub.org/study/representativeness-of-participants-eligible-to-be-enrolled-in-34499725","doi":"10.1001/jama.2021.15286","journal":"JAMA","n_participants":null,"pmid":"34499725","source_url":"https://pubmed.ncbi.nlm.nih.gov/34499725/","study_design":null,"title":"Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment","title_match":true,"year":2021},{"alzhub_score":52,"alzhub_url":"https://alzhub.org/study/lifetime-cost-effectiveness-of-lecanemab-for-early-alzheimer-s-disease-41694525","doi":"10.3389/fpubh.2026.1692508","journal":"Frontiers in public health","n_participants":null,"pmid":"41694525","source_url":"https://pubmed.ncbi.nlm.nih.gov/41694525/","study_design":null,"title":"Lifetime cost-effectiveness of lecanemab for early Alzheimer's disease","title_match":false,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/brain-resident-myeloid-cells-promote-rapid-leukocyte-adhesion-in-005bc584","doi":"10.64898/2026.09.07.749938","journal":"bioRxiv","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.64898/2026.09.07.749938","study_design":"longitudinal study","title":"Brain-resident myeloid cells promote rapid leukocyte adhesion in leptomeningeal vessels after anti-A\u03b2 immunotherapy","title_match":false,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/anti-amyloid-immunotherapy-drives-apoe4-specific-increases-in-glial-922ec944","doi":"10.64898/2026.06.26.734793","journal":"bioRxiv","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.64898/2026.06.26.734793","study_design":null,"title":"Anti-amyloid immunotherapy drives APOE4 specific increases in glial reactivity, perivascular immune activation, and ARIA-like events","title_match":false,"year":2026},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/open-peer-commentary-to-failure-to-demonstrate-efficacy-of-aducanumab-33135288","doi":"10.1002/alz.12235","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"33135288","source_url":"https://pubmed.ncbi.nlm.nih.gov/33135288/","study_design":"clinical trial","title":"Open Peer Commentary to \u201cFailure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019\u201d","title_match":true,"year":2020},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/o40405-aducanumab-biib037-an-antiamyloid-beta-monoclonal-antibody-in-204cb97e","doi":"10.1016/j.jalz.2015.07.367","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1016/j.jalz.2015.07.367","study_design":null,"title":"O4\u201004\u201005: Aducanumab (BIIB037), an anti\u2010amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double\u2010blind, placebo\u2010controlled, phase 1b study","title_match":true,"year":2015},{"alzhub_score":62,"alzhub_url":"https://alzhub.org/study/trailblazer-alz-4-topline-study-results-directly-comparing-donanemab-7521651f","doi":"10.1192/bjo.2023.227","journal":"BJPsych Open","n_participants":148,"pmid":null,"source_url":"https://doi.org/10.1192/bjo.2023.227","study_design":"clinical trial","title":"TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease","title_match":true,"year":2023},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/randomized-double-blind-placebo-controlled-studies-to-evaluate-5b6a5200","doi":"10.1212/wnl.86.16_supplement.s1.003","journal":"Neurology","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1212/wnl.86.16_supplement.s1.003","study_design":"clinical trial","title":"Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer\u2019s Disease: Phase 3 Study Design (S1.003)","title_match":true,"year":2016},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/aducanumab-36-month-data-from-prime-a-randomized-double-blind-placebo-12a02583","doi":"10.1212/wnl.90.15_supplement.s2.004","journal":"Neurology","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1212/wnl.90.15_supplement.s2.004","study_design":"clinical trial","title":"Aducanumab 36-month data from PRIME: a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer\u2019s disease (S2.004)","title_match":true,"year":2018},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/immunotherapy-with-aducanumab-restores-calcium-homeostasis-in-tg2576-aa97eb96","doi":"10.1523/jneurosci.2080-16.2016","journal":"The Journal of Neuroscience","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1523/jneurosci.2080-16.2016","study_design":null,"title":"Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice","title_match":true,"year":2016},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/from-monomer-to-fibril-abetaamyloid-binding-to-aducanumab-antibody-87e1c4ad","doi":"10.1002/prot.25978","journal":"Proteins: Structure, Function, and Bioinformatics","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1002/prot.25978","study_design":null,"title":"From monomer to fibril: Abeta\u2010amyloid binding to Aducanumab antibody studied by molecular dynamics simulation","title_match":true,"year":2020},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/anti-a-antibody-aducanumab-regulates-the-proteome-of-senile-plaques-af6534d7","doi":"10.3233/jad-200715","journal":"Journal of Alzheimer's Disease","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.3233/jad-200715","study_design":null,"title":"Anti-A\u03b2 Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer\u2019s Disease","title_match":true,"year":2021},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/aducanumab-for-alzheimer-s-disease-an-update-3dd6d026","doi":"10.31117/neuroscirn.v4i2.81","journal":"Neuroscience Research Notes","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.31117/neuroscirn.v4i2.81","study_design":null,"title":"Aducanumab for Alzheimer's disease: An update","title_match":true,"year":2021},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/aducanumab-a-new-phase-in-therapeutic-development-for-alzheimers-f2e71f9d","doi":"10.15252/emmm.202114781","journal":"EMBO Molecular Medicine","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.15252/emmm.202114781","study_design":null,"title":"Aducanumab: a new phase in therapeutic development for Alzheimer\u2019s disease?","title_match":true,"year":2021},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/a-primer-on-the-evolution-of-aducanumab-the-first-antibody-approved-4e65c051","doi":"10.3233/jad-215065","journal":"Journal of Alzheimer's Disease","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.3233/jad-215065","study_design":null,"title":"A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer\u2019s Disease","title_match":true,"year":2021},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/aducanumab-and-disease-modifying-treatments-for-alzheimer-s-disease-6ea281e6","doi":"10.1002/pnp.711","journal":"Progress in Neurology and Psychiatry","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1002/pnp.711","study_design":null,"title":"Aducanumab and disease modifying treatments for Alzheimer's disease","title_match":true,"year":2021},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/caso-de-aducanumab-mas-esperanza-que-ciencia-27930c38","doi":"10.11565/arsmed.v46i3.1826","journal":"ARS MEDICA Revista de Ciencias M\u00e9dicas","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.11565/arsmed.v46i3.1826","study_design":null,"title":"caso de aducanumab \u00bfM\u00e1s esperanza que ciencia?","title_match":true,"year":2021},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/population-pharmacokinetics-and-standard-uptake-value-ratio-of-098ca6fa","doi":"10.1002/psp4.12728","journal":"CPT: Pharmacometrics & Systems Pharmacology","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1002/psp4.12728","study_design":null,"title":"Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque\u2013removing agent, in patients with Alzheimer\u2019s disease","title_match":true,"year":2021},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/computational-approaches-for-supporting-combination-therapy-in-the-80f66de5","doi":"10.3233/adr-210039","journal":"Journal of Alzheimer's Disease Reports","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.3233/adr-210039","study_design":null,"title":"Computational Approaches for Supporting Combination Therapy in the Post-Aducanumab Era in Alzheimer\u2019s Disease","title_match":true,"year":2021},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/is-aducanumab-for-lmics-promises-and-challenges-8f1e1182","doi":"10.3390/brainsci11111547","journal":"Brain Sciences","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.3390/brainsci11111547","study_design":null,"title":"Is Aducanumab for LMICs? Promises and Challenges","title_match":true,"year":2021},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/consensus-statement-regarding-the-application-of-biogen-to-health-b7d8f16f","doi":"10.5770/cgj.24.570","journal":"Canadian Geriatrics Journal","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5770/cgj.24.570","study_design":null,"title":"Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab","title_match":true,"year":2021},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/new-drug-update-dostarlimab-loncastuximab-tesirine-and-aducanumab-c153db12","doi":"10.4140/tcp.n.2022.9","journal":"The Senior Care Pharmacist","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.4140/tcp.n.2022.9","study_design":null,"title":"New Drug Update: Dostarlimab, Loncastuximab Tesirine, and Aducanumab","title_match":true,"year":2022},{"alzhub_score":74,"alzhub_url":"https://alzhub.org/study/clinical-application-of-plasma-p-tau217-to-assess-eligibility-for-38971815","doi":"10.1186/s13195-024-01521-9","journal":"Alzheimer's research & therapy","n_participants":150,"pmid":"38971815","source_url":"https://pubmed.ncbi.nlm.nih.gov/38971815/","study_design":"cohort study","title":"Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer's disease","title_match":false,"year":2024},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/precision-medicine-analysis-of-heterogeneity-in-individual-level-37882364","doi":"10.1002/alz.13431","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"37882364","source_url":"https://pubmed.ncbi.nlm.nih.gov/37882364/","study_design":null,"title":"Precision medicine analysis of heterogeneity in individual-level treatment response to amyloid beta removal in early Alzheimer's disease","title_match":false,"year":2024}]}